Products for Research Use Only

DEBIO 1143

CAT: 0013-GTR19163952-01Size: 1 gDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19163952-01Size:1 g
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
DEBIO 1143 (AT-406, DEBIO-1143, SM406, ARRY-334543, D1143) is potent, orally active Smac mimetic that antagonizes cIAP1, cIAP2 and XIAP with Ki of 66.4, 1.9 and 5.1 nM, respectively; effectively antagonizes XIAP BIR3 protein in cell-free functional assays, induces rapid degradation of cellular cIAP1 protein, and inhibits cancer cell growth in various human cancer cell lines; effectively induces apoptosis and causes complete inhibition of tumor growth apoptosis in xenograft tumors.Ovarian Cancer Phase 2 Clinical (In Vitro) :Xevinapant mimic closely the AVPI peptide in both hydrogen bonding and hydrophobic interactions with XIAP, with additional hydrophobic contacts with W323 of XIAP. Xevinapant is more sensitive to these IAPs than Smac AVPI peptide with 50-100 fold binding affinities. Xevinapant (1 μM) completely restores the activity of caspase-9, which is suppressed by 500 nM XIAP BIR3 in a cell-free system. In MDA-MB-231 cell, Xevinapant induces rapid cellular cIAP1 degradation and also pulls down the cellular XIAP protein. Xevinapant effectively inhibits lots of human cancer cell lines and shows IC50 of 144 and 142 nM in MDA-MB-231 cell and SK-OV-3 ovarian cell, with low toxicity against normal-like human breast epithelial MCF-12F cells and primary human normal prostate epithelial cells. Xevinapant induces apoptosis in MDA-MB-231 cell by inducing activation of caspase-3 and cleavage of PARP. Xevinapant displays single agent activity in ovarian cancer cell lines. The IC50 values of AT-406 in these ovarian cancer cells range from 0.05-0.5 μg/mL. Xevinapant exhibits anti-ovarian cancer efficacy both as a single agent and in combination with carboplatin. Xevinapant (30 μg/mL) induced degradation of XIAP in the drug sensitive ovarian cancer cell lines. (In Vivo) :Xevinapant (AT-406) is very effective in inhibition of tumor growth in the MDA-MB-231 xenograft model, and has minimal toxicity to animals. Xevinapant is evaluated for its pharmacokinetic (PK) properties in mice, rats, non-human primates and dogs.
CAS Number
1071992-99-8
Product Name Alternative
AT-406 | DEBIO1143 | SM406 | ARRY-334543 | D1143
Purity
>98% (HPLC)
Solubility
DMSO: 93 mg/mL (165.6 mM) ; Ethanol: 93 mg/mL (165.6 mM) ; Water: <1 mg/mL (< 1 mg/ml refers to the product slightly soluble or insoluble)
Smiles
CC (C) CC (=O) N1CCC2CCC (N2C (=O) C (C1) NC (=O) C (C) NC) C (=O) NC (C3=CC=CC=C3) C4=CC=CC=C4
Molecular Formula
C32H43N5O4
Molecular Weight
561.727
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
(5S,8S,10aR) -N-benzhydryl-5- ((S) -2- (methylamino) propanamido) -3- (3-methylbutanoyl) -6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide

Chemical Information

Xevinapant

Xevinapant is an orally available mimetic of the natural second mitochondrial-derived activator of caspases (Smac) and inhibitor of Inhibitor of Apoptosis Proteins (IAPs), with potential immunomodulating, apoptotic-inducing, chemo-radio-sensitizing and antineoplastic activities. Upon oral administration,xevinapant targets and binds to the Smac binding groove on IAPs, including the direct caspase inhibitor X chromosome-linked IAP (XIAP), and the cellular IAPs 1 (c-IAP1) and 2 (c-IAP2). This inhibits the activities of these IAPs and promotes the induction of apoptosis. Additionally, as xevinapant inhibits the activity of IAPs, it may work synergistically with cytotoxic drugs and/or radiation to overcome tumor cell resistance to apoptosis. As IAPs regulate nuclear factor-kappa B (NFkB) signaling pathways, which drives the expression of genes involved in immune and inflammatory responses, xevinapant may enhance anti-tumor immune responses when administered with certain immunomodulating agents, such as immune checkpoint inhibitors. IAPs are overexpressed by many cancer cell types and suppress both intrinsic and extrinsic apoptosis by binding to and inhibiting active caspases via their baculoviral lAP repeat (BIR) domains. They contribute to chemo-radio-resistance of cancer cells to certain cytotoxic agents and radiation, promote tumor cell survival and are associated with poor prognosis in certain types of cancer. SMAC, a pro-apoptotic mitochondrial protein, is an endogenous inhibitor of the IAPs family of cellular proteins.

CAS Number1071992-99-8
PubChem CID25022340
IUPAC Name(5S,8S,10aR)-N-benzhydryl-5-[[(2S)-2-(methylamino)propanoyl]amino]-3-(3-methylbutanoyl)-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide
Molecular FormulaC32H43N5O4
Molecular Weight561.7
XLogP3.1
Topological Polar Surface Area111
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count5
Rotatable Bond Count9
Heavy Atom Count41
Formal Charge0
Complexity896
SMILES
C[C@@H](C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)CC(C)C)NC
InChI
InChI=1S/C32H43N5O4/c1-21(2)19-28(38)36-18-17-25-15-16-27(37(25)32(41)26(20-36)34-30(39)22(3)33-4)31(40)35-29(23-11-7-5-8-12-23)24-13-9-6-10-14-24/h5-14,21-22,25-27,29,33H,15-20H2,1-4H3,(H,34,39)(H,35,40)/t22-,25+,26-,27-/m0/s1
InChIKey
LSXUTRRVVSPWDZ-MKKUMYSQSA-N
Chemical Structure
2D Structure
2D structure of Xevinapant
CAS: 1071992-99-8
CID: 25022340
Formula: C32H43N5O4
MW: 561.7
Interactive 3D Structure
Loading 3D structure...
Computed Properties
PropertyValue
Molecular Weight561.7
XLogP33.1
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count5
Rotatable Bond Count9
Exact Mass561.33150487
Monoisotopic Mass561.33150487
Topological Polar Surface Area111 Ų
Heavy Atom Count41
Formal Charge0
Complexity896
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes